Analysis for DHR
- 📈 Growth — 22/30
- 💰 Profitability — 16/20
- 🏦 Financial Health — 18/20
- 💵 Valuation — 12/20
- ⚠️ Risk — 6/10
Summary:
📈 Growth & Financial Trajectory
Over the 8 quarters, Revenues moved from roughly the 6.5B level in 2024 to a peak around 6.84B in 2025-Q4, then eased to about 5.95B in 2026-Q1. Net Income fluctuated, about $0.95B in early 2025, dipping to ~$0.56B in 2025-Q4, then rebounding to ~$1.03B in 2026-Q1. Gross Margin stayed in the high-50s to low-60s; Operating Margin hovered in the high-teens.
💰 Margins & Cash Flow
Gross Margin ~58–62%; Operating Margin ~18–22%; Net cash flow from operating activities generally positive across quarters, with investing swings driving quarterly cash-flow variability. Several periods show positive operating cash flow while overall free cash flow fluctuates due to investing activity.
🛡️ Balance Sheet & Liquidity
Total Assets ≈ $80–83B; Equity ≈ $49–53B; Long-term Debt ≈ $16–19B. Current Assets roughly $9–14B vs Current Liabilities about $6–7B. Balance sheet strength and a solid liquidity cushion support near-term commitments.
⚠️ Key Drivers & Risks
- Drivers: Strong demand in Life Sciences instrumentation/diagnostics; diversified product mix.
- Risks: Quarterly profit swings and cyclicality; valuation sensitivity to macro/rate changes.